



University of Nebraska
Medical Center™

Nebraska Medicine



FINAL PROGRAM



2018


Pan Pacific Lymphoma Conference

July 16-20 | Hyatt Regency Maui Resort & Spa | Lahaina, Hawaii

Co-sponsored by the University of Nebraska Medical Center and Postgraduate Institute for Medicine

 **#PPLC18**

Download the event app



Stay up-to-date on PPLC 2018 by downloading the **FREE** event app!

1. Search for the “**eventScribe**” app in the Apple App Store or in Google Play or scan the QR code below.
2. Search for “**UNMC**” inside the eventScribe app.
3. Login or create an account.



Laptop and other mobile device users, go to **bit.ly/unmc2018**.

We gratefully acknowledge the following for support of this conference:

EDUCATIONAL GRANT SUPPORT

AbbVie Inc.
Acerta Pharma, a member of the AstraZeneca Group
Bayer HealthCare Pharmaceuticals, Inc.
Celgene Corporation
Epizyme, Inc.
Genentech, Inc.
Pharmacyclics, LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Sandoz Inc., a Novartis Division
Seattle Genetics, Inc.
TG Therapeutics, Inc.

PLATINUM SUPPORTER

Pharmacyclics, LLC, an AbbVie Company, and Janssen Biotech, Inc.

GOLD SUPPORTERS

AbbVie Inc.
AstraZeneca and Acerta Pharma, a member of the AstraZeneca Group
Gilead Sciences, Inc.

BRONZE SUPPORTER

Takeda Oncology

COPPER SUPPORTERS

Amgen
Bayer HealthCare Pharmaceuticals, Inc.
Celgene Corporation
Genentech, Inc.
Karyopharm Therapeutics Inc.
Novartis Oncology
Seattle Genetics, Inc.
Spectrum Pharmaceuticals, Inc.

SUPPORTER

Harborside Press

EXHIBITORS

AbbVie Inc.
Amgen
AstraZeneca
Bayer HealthCare Pharmaceuticals, Inc.
Celgene Corporation
Genentech, Inc.
Gilead Sciences, Inc.
Karyopharm Therapeutics Inc.
Kite, a Gilead Company
Novartis Oncology
Pharmacyclics, LLC, an AbbVie Company, and Janssen Biotech, Inc.
Seattle Genetics, Inc.
Spectrum Pharmaceuticals, Inc.
Takeda Oncology

Aloha

Dear Friends and Colleagues,

Welcome to the 2018 Pan Pacific Lymphoma Conference!

Since its inception in 1994, PPLC has grown and become a premier international conference on the latest advances in lymphoma, with over 550 attendees representing 17 countries. Expert faculty will present in **scientific sessions** to cover Bench to Bedside, Novel Therapies in Lymphoma, High Grade B-Cell Lymphomas, Aggressive T-Cell Lymphomas, Hodgkin Lymphoma, Multiple Myeloma/Plasma Cell Dyscrasia, Common Indolent Lymphomas, and Uncommon Indolent Lymphomas. This year, Matthew Davids, MD, MMSc will present the **First James O. Armitage Lymphoma Clinical Investigator Award Lecture** and David G. Maloney, MD, PhD will deliver the **First Oliver Press Memorial Lecture**, "Update on CAR T-Cell Therapies for NHL," in memory of our esteemed colleague, Oliver W. Press, MD, PhD.

On Monday, we will feature an **Interprofessional Education Day**, with presentations on the Future Trends in Lymphoma Care/Administrative and Economic Implications, Immunotherapy, CAR T-Cell Toxicities and Team Management, Pharmacologic Supportive Care, Ethical Considerations, Geriatric Oncology for Patients with Lymphoma, and Survivorship – Fertility and Sexual Issues in Lymphoma Patients.

Please make sure to join us on Tuesday and Thursday afternoons for the **Ask the Experts** sessions where we will discuss clinical cases on a variety of topics. On Wednesday, we will have our fast-paced **Lymphoma Jeopardy** with four teams competing in the Pineapple Cup Lymphoma Jeopardy Semifinals!


In the Monarchy Ballroom, there will be **posters** detailing the latest research in lymphoma and transplantation. Also, remember to visit the **exhibits** in the Grand Promenade. Join the industry-supported **satellite symposiums** in the afternoons on Monday through Thursday.

We have also planned two evening functions so you can meet and network with other conference attendees. On Tuesday evening, light hors d'oeuvres and beverages will be served at the **Welcome Reception** in the Napili Gardens from 7-9 pm. Thursday evening's **Conference Dinner** in the Halona Kai will be from 7-10 pm with dinner and beverages served while we enjoy a live band performance.

Please be sure that you and your paid guests wear your conference badge at all times. The attire for this conference is casual; layered clothing is recommended as temperature in meeting rooms can fluctuate. A light jacket or sweater for outdoor evening activities is suggested. Leave your ties in your room!

Thank you for joining us at the 2018 Pan Pacific Lymphoma Conference. Welcome to Hawaii!

Conference Directors




James O. Armitage, MD

Joe Shapiro Professor of Medicine
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center



Susan Blumel, RN, BSN

Clinical Study Nurse Coordinator
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center



Matthew A. Lunning, DO

Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center



Julie M. Vose, MD, MBA

Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center

CONFERENCE REGISTRATION INFORMATION

The Conference Registration and Information Desk is located in the Grand Promenade on the Promenade Level of the Hyatt Regency Maui Resort & Spa. Attendees may pick up their conference materials and name badges at this location. The Registration/Information Desk is open during the following times:

Sunday, July 15	2:00 p.m. - 4:00 p.m.
Monday, July 16	7:00 a.m. - 12:00 p.m. 2:00 p.m. - 4:00 p.m.
Tuesday, July 17	7:00 a.m. - 12:00 p.m.
Wednesday, July 18	7:00 a.m. - 12:00 p.m.
Thursday, July 19	7:00 a.m. - 12:00 p.m.
Friday, July 20	7:00 a.m. - 12:00 p.m.

SESSIONS AND ROOM ASSIGNMENTS

GRAND PROMENADE G

Conference Registration
Continental Breakfast
Refreshment Breaks
Exhibits

HALONA KAI H

Conference Dinner — Thursday, July 19 from 7-10 p.m.

MONARCHY BALLROOM 1-4 M

Scientific Sessions
Ask the Experts
Lymphoma Jeopardy
Poster Presentations

MONARCHY BALLROOM 5-7 M

Satellite Symposiums

NAPILI GARDENS N

Welcome Reception — Tuesday, July 17 from 7-9 p.m.

INTERNET ACCESS I

Complimentary WiFi is available in the conference area.

Network: UNMCPPLC18

Password: PPLC2018

Internet cafe is available in Maui Suite 5 on the Promenade Level and can be accessed during conference session hours.

In-room complimentary WiFi for guests of the Hyatt Regency Maui Resort & Spa.

MOBILE DEVICE USE

We encourage you to use your mobile device to download the 2018 PPLC event app so you can have access to the entire conference program. Please remember to turn your mobile device to silent or vibrate mode when attending sessions.

POSTER AND EXHIBIT HOURS

Monday, July 16	7:00 a.m. - 12:00 p.m.
Tuesday, July 17	7:00 a.m. - 12:00 p.m.
Wednesday, July 18	7:00 a.m. - 12:00 p.m.
Thursday, July 19	7:00 a.m. - 12:00 p.m.
Friday, July 20	7:00 a.m. - 10:00 a.m.

PHOTOGRAPHY AND AUDIO VISUAL RECORDING POLICY

Please be aware that during the 2018 Pan Pacific Lymphoma Conference, attendees, vendors, guests, and exhibitors may be photographed or videotaped by UNMC and/or third parties authorized by UNMC. Some of these photographs or videos may be displayed by UNMC in future publications or other materials. By virtue of your attendance, you agree to allow UNMC to use photographs of you in these promotional materials.

Photographs taken for the purpose of sharing on social media are allowed, but should avoid showing presentation slides. Please use #PPLC18 when posting on social media.

CHILDREN AND OTHER ACCOMPANYING GUESTS




PPLC 2018 does not offer childcare services. Due to limited seating capacity and the highly technical nature of the program, children are not allowed to attend sessions. For their safety, children must be accompanied by an adult at all times during the conference.

Registered accompanying guests may join conference registrants at the following food functions:

- Continental breakfasts (7-9 a.m.) and breaks as part of the main conference from Monday through Friday
- Welcome Reception on Tuesday evening
- Conference Dinner on Thursday evening

Name badges will be required at these conference food functions.

VENUE FLOOR PLAN



TARGET AUDIENCE

The 2018 Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. The 2018 event will benefit members of the multidisciplinary lymphoma team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

CONFERENCE OBJECTIVES

At the conclusion of the conference, the participant should be better able to:

1. Evaluate results of clinical trials with current and emerging agents and regimens to develop evidence-based clinical management strategies in patients with Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)
2. Formulate evidence-based management strategies for the optimal management of patients with lymphoma, leukemia and myeloma, inclusive of multi-modality therapies and maintenance-based regimens
3. Analyze underlying molecular and cytogenetic abnormalities contributing to hematologic malignancies and their impact on diagnosis, prognosis, and therapeutic approaches
4. Evaluate the optimal patient selection, timing, and regimen for stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy for patients with lymphoma
5. Personalize the treatment of hematologic malignancies based upon patient and disease-specific characteristics, and manage treatment-related adverse effects appropriately
6. Provide accurate and appropriate counsel as part of the treatment plan
7. Review factors that impact patient selection, availability, and enrollment into clinical trials examining novel agents under investigation in patients with lymphoma, leukemia, and myeloma

DISCLOSURE DECLARATION

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, the Accreditation Council for Continuing Medical Education, the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, the American Nurses Credentialing Center's Commission on Accreditation and the Postgraduate Institute for Medicine to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities.

All planning committee members and conference faculty are required to disclose to the audience any financial interest or other relationship he/she has with any commercial interests. Conference faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in the conference online proceedings and app so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This conference may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the conference sponsors.

The planning committee members listed below have no financial relationships to disclose.

All faculty conflicts of interest are noted in the online proceedings and app.

Trace Hutchison, PharmD — *No conflicts of interest*
Postgraduate Institute for Medicine

Heidi Keeler, PhD, RN — *No conflicts of interest*
University of Nebraska Medical Center

Samantha Mattiucci, PharmD, CHCP — *No conflicts of interest*
Postgraduate Institute for Medicine

Renee Paulin, MSN, RN, CWOCN — *No conflicts of interest*
University of Nebraska Medical Center

Brenda C. Ram, CMP, CHCP — *No conflicts of interest*
University of Nebraska Medical Center

Judi Smelker-Mitchek, RN, BSN — *No conflicts of interest*
Postgraduate Institute for Medicine

CONTINUING EDUCATION CREDIT

PHYSICIANS

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 29 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant

to earn up to 29 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) programs. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.*

Through the American Board of Medical Specialties (ABMS) ongoing commitment to increase access to practice relevant Maintenance of Certification (MOC) Activities through the ABMS Continuing Certification Directory, the 2018 Pan Pacific Lymphoma Conference has met the requirements as an MOC Part II CME Activity (apply toward general CME requirement) and/or an MOC Part II Self-Assessment Activity for the following ABMS Member Boards:

MOC Part II CME Activity

American Board of Internal Medicine (ABIM)

American Board of Pathology (ABP)

*Important note: ABIM requires you to claim CME credit in order to issue MOC points for this activity.

NURSES

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is provided for up to 29.0 contact hours under ANCC criteria.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center's Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) (provider), University of Nebraska Medical Center, Center for Continuing Education (UNMC CCE), and the Postgraduate Institute for Medicine (PIM).

PHARMACISTS

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 25.75 contact hours (0.2575 CEUs) of the Accreditation Council for Pharmacy Education.

In order to obtain your statement of credit, you must register for the conference, document attendance, and complete an online evaluation form. **For pharmacists:** Transcript information will be sent to the NABP CPE Monitor Service within 6 weeks. To receive your official statement of credit, you must go to your NABP e-profile to print an individual statement of credit or a transcript.

How to Claim Credit

Physicians claiming MOC credit:

To obtain credit, you must complete the evaluation in the app.

1. On the front screen, select the gray tile entitled Evaluation
2. Complete the UPDATE PROFILE information
3. Complete the pretest for MOC credit
4. Select the Scientific Sessions you attended and complete the evaluation for each session
5. Complete the general conference evaluation
6. Complete the post test for MOC credit
7. Retrieve your certificate

Non-Physicians or Physicians not claiming MOC credit:

To obtain credit, you must complete the evaluation in the app.

1. On the front screen, select the gray tile entitled Evaluation
2. Complete the UPDATE PROFILE information
3. Select the Scientific Sessions you attended and complete the evaluation for each session
4. Complete the general conference evaluation
5. Retrieve your certificate


THE DEADLINE TO CLAIM CREDIT FOR THIS CONFERENCE IS SEPTEMBER 16, 2018.

Claiming Pharmacy Credit:

In order for pharmacists to claim credit for their participation in the conference, each individual must complete the evaluation in the conference app, and ensure that their date of birth (mm/dd), as well as their NABP ID # is on record with UNMC/CCE. Your NABP ID# is different than your license number.

Pharmacists have up to **30 days** to complete the evaluation and claim credit for participation. UNMC CCE will supply the necessary information to Postgraduate Institute for Medicine for submission to the CPE Monitor.

THERE WILL BE NO REQUESTS FOR SUBMISSION ACCEPTED AFTER AUGUST 20, 2018.



*Monday, July 16***Interprofessional Education Day**

7:00 a.m. Conference Registration
Continental Breakfast

G

7:45 a.m. Welcome
Matthew A. Lunning, DO

M

SCIENTIFIC SESSIONS

M

MODERATORS: Susan Blumel, RN, BSN/Matthew A. Lunning, DO

8:00 a.m. Future Trends in Lymphoma Care/
Administrative and Economic Implications
Philip J. Bierman, MD and Theresa Franco, MSN, RN

8:40 a.m. Immunotherapy
Laura Zitella, MS, RN, ACNP-BC, AOCN

9:10 a.m. CAR T-Cell Toxicities and Team Management
Susan Blumel, RN, BSN

9:40 a.m. Pharmacologic Supportive Care
Susanne E. Liewer, PharmD, BCOP, FHOPA

10:10 a.m. Refreshment Break

G

10:25 a.m. Ethical Considerations (Medical Marijuana,
Physician Assisted Suicide, Navigating
Alternative Therapies During Treatment)
Sandra E. Kurtin, PhD, APN-C, AOCN and R. Gregory
Bociek, MD, MSc, FRCP(C)

11:05 a.m. Geriatric Oncology for Patients with Lymphoma
Peggy Burhenn, MS, RN-BC, AOCNS

11:35 a.m. Survivorship – Fertility and Sexual Issues in
Lymphoma Patients
Katrina P. Sabati, MPA, PA-C

12:15 p.m. Adjourn

SATELLITE SYMPOSIUMS

M

1:00 p.m. Dissecting the Decision: Documenting and
Discussing the Clinical Practice Patterns of
Hematologic Oncology Investigators in the
Management of Follicular Lymphoma
Educational grant support provided by Bayer
HealthCare Pharmaceuticals, Inc., Celgene
Corporation, and Genentech, Inc.

3:00 p.m. Clinical Trials and Outcomes in Relapsed/
Refractory CLL
Educational grant support provided by Gilead Sciences,
Inc., TG Therapeutics, Inc., and Verastem Oncology

5:00 p.m. Adjourn

Tuesday, July 17

7:00 a.m. Continental Breakfast

G

7:30 a.m. Welcome
Julie M. Vose, MD, MBA

M

SCIENTIFIC SESSIONS

M

Bench to Bedside

MODERATORS: Julie M. Vose, MD, MBA/Daniel J. DeBehnke, MD, MBA

7:40 a.m. Update on the WHO Classification of Lymphoma
Timothy C. Greiner, MD

8:05 a.m. Immune Evasion and Engagement in Lymphoma
Stephen M. Ansell, MD, PhD

8:30 a.m. Clinical Use of Cell Free DNA in Lymphoma
David M. Kurtz, MD, PhD

8:55 a.m. Clinical Applications of Genomic Studies in NHL
Andrew D. Zelenetz, MD, PhD

9:20 a.m. *First James O. Armitage Lymphoma Clinical
Investigator Award*
Matthew S. Davids, MD, MMSc

9:50 a.m. Refreshment Break

G

G Grand Promenade

H Halona Kai

M Monarchy Ballroom 1-4

M Monarchy Ballroom 5-7

N Napili Gardens

Novel Therapies in Lymphoma

MODERATORS: Richard I. Fisher, MD

- 10:05 a.m.** **First Oliver Press Memorial Lecture**
Update on CAR T-Cell Therapies for NHL
David G. Maloney, MD, PhD
- 10:30 a.m.** Novel Cell Pathway Targeted Agents for Lymphoma Therapy
Julie M. Vose, MD, MBA
- 10:55 a.m.** Novel-Novel Drug Combination in B-Cell Malignancies
Kieron M. Dunleavy, MD
- 11:20 a.m.** New Monoclonal Antibodies and Antibody Drug Conjugates
Brad S. Kahl, MD
- 11:45 a.m.** How Do We Incorporate PET/CT Scanning into Standard of Care and Research Studies?
Bruce D. Cheson, MD
- 12:10 p.m.** Use of Deauville Versus Delta SUV in Response Evaluation for Lymphoma
Neil J. Hansen, MD
- 12:35 p.m.** Adjourn

SATELLITE SYMPOSIUM

M

- 1:00 p.m.** The Next Steps in CAR T-Cell Therapy for the Treatment of Patients with Lymphoma
Educational grant support provided by Celgene Corporation and Kite, a Gilead Company

ASK THE EXPERTS

M

- 3:00 p.m.** Clinical Cases Discussing Timing, Responses, and Toxicity of CAR T-Cell Therapy for CD19+ Non-Hodgkin Lymphoma
MODERATOR: R. Gregory Bociek, MD, MSc, FRCP(C)
Leo I. Gordon, MD, FACP; Stephen J. Schuster, MD; and Julie M. Vose, MD, MBA
- 4:00 p.m.** Clinical Cases Discussing Upfront, Relapsed, and Transplant Options for Patients with Multiple Myeloma
MODERATOR: Matthew A. Lunning, DO
Sarah A. Holstein, MD, PhD and Sagar Lonial, MD
- 5:00 p.m.** Adjourn

WELCOME RECEPTION

N

7:00-9:00 p.m.

Conference participants and registered accompanying guest(s) are invited to join the reception. Name tags required.

Wednesday, July 18

- 7:00 a.m.** Continental Breakfast

G

SCIENTIFIC SESSIONS

M

High Grade B-Cell Lymphomas

MODERATORS: Wyndham H. Wilson, MD, PhD/Daniel J. DeBehnke, MD, MBA

- 7:30 a.m.** Update on Pathology for High Grade B-Cell Lymphomas (HGBCL)
Timothy C. Greiner, MD
- 7:55 a.m.** Optimum Therapy for Standard Risk HGBCL
Nancy L. Bartlett, MD
- 8:20 a.m.** Upfront Therapies For HGBCL With Comorbidities
Laurie H. Sehn, MD, MPH
- 8:45 a.m.** Therapy for Double/Triple Hit HGBCL
Sonali M. Smith, MD
- 9:10 a.m.** Relapsed and Refractory DLBCL – Role of HDT-ASCR in the ERA of CAR T-Cell Therapy
Craig H. Moskowitz, MD
- 9:35 a.m.** Burkitt Lymphoma – R-EPOCH for All?
Mark J. Roschewski, MD
- 10:00 a.m.** Concurrent Systemic and CNS Aggressive NHL: How to Manage?
Philip J. Bierman, MD
- 10:25 a.m.** Refreshment Break

G

Aggressive T-Cell Lymphomas

MODERATORS: Matthew A. Lunning, DO/Tara M. Graff, DO, MS

- 10:40 a.m.** Update on T-Cell Lymphomas in WHO Classification
Dennis D. Weisenburger, MD

- 11:05 a.m.** Therapy for CD 30+ PTCL Subtypes
Steven M. Horwitz, MD
- 11:30 a.m.** Treatment for Tumor Stage/Transformed Mycosis Fungoides
Youn H. Kim, MD
- 11:55 a.m.** NK/T-Cell Lymphoma: Updated Therapies and Improved Outcomes
Won Seog Kim, MD, PhD
- 12:20 p.m.** You Make the Call: Transplant in T-Cell Lymphoma Subtypes
Sonali M. Smith, MD; Kerry J. Savage, MD, MSc; and Jasmine M. Zain, MD
- 12:45 p.m.** Adjourn

SATELLITE SYMPOSIUM

M

- 1:00 p.m.** Dissecting the Decision: Documenting and Discussing the Clinical Practice Patterns of Hematologic Oncology Investigators in the Management of Chronic Lymphocytic Leukemia
Educational grant support provided by AbbVie Inc., AstraZeneca Pharmaceuticals LP, and Genentech, Inc.

LYMPHOMA JEOPARDY

M

Semi-Finals

MODERATOR: Matthew A. Lunning, DO

- 3:00 p.m.** Pineapple Cup Lymphoma Jeopardy Semifinals #1
TEAM 1: Kieron M. Dunleavy, MD; Jeremy S. Abramson, MD; Nathan H. Fowler, MD; and Matthew S. Davids, MD, MMSc
TEAM 2: Steven M. Horwitz, MD; Brad S. Kahl, MD; Kerry J. Savage, MD, MSc; and Sonali M. Smith, MD
- 4:00 p.m.** Pineapple Cup Lymphoma Jeopardy Semifinals #2
TEAM 3: David G. Maloney, MD, PhD; Richard I. Fisher, MD; Bruce D. Cheson, MD; and Leo I. Gordon, MD, FACP
TEAM 4: Wyndham H. Wilson, MD, PhD; Thomas E. Witzig, MD; Jonathan W. Friedberg, MD, MMSc; and Ranjana H. Advani, MD
- 5:00 p.m.** Adjourn

Thursday, July 19

- 7:00 a.m.** Continental Breakfast

G

SCIENTIFIC SESSIONS

M

Hodgkin Lymphoma

MODERATORS: Theresa Franco, MSN, RN/Thomas E. Witzig, MD

- 7:20 a.m.** Hodgkin Upfront Therapy in Germany vs the US
Ranjana H. Advani, MD and Andreas Engert, MD
- 7:55 a.m.** Use of Total Metabolic Tumor Volume (TMTV) in PET Scans
Neil J. Hansen, MD
- 8:20 a.m.** Radiation Therapy for Localized LP Hodgkin
Richard T. Hoppe, MD
- 8:45 a.m.** Hodgkin Lymphoma: First Relapse Options
Barbara Pro, MD
- 9:10 a.m.** Transplant in Hodgkin Lymphoma: Still After First Relapse?
Craig H. Moskowitz, MD
- 9:35 a.m.** Beyond Check Point Inhibitors for Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD

- 10:00 a.m.** Refreshment Break

G

Multiple Myeloma/Plasma Cell Dyscrasia

MODERATORS: Eric J. Avery, MD/Julie M. Vose, MD, MBA

- 10:20 a.m.** New Induction Therapies for Multiple Myeloma
Sarah A. Holstein, MD, PhD
- 10:45 a.m.** Relapsed and Refractory Multiple Myeloma – Sequencing Therapies
Sagar Lonial, MD
- 11:10 a.m.** Castleman's Disease
Angela Dispenzieri, MD
- 11:35 a.m.** Amyloid Management
Angela Dispenzieri, MD
- 12:00 p.m.** Pineapple Cup Lymphoma Finals
Winners from Preliminaries
- 12:30 p.m.** Adjourn

SATELLITE SYMPOSIUM M

- 1:00 p.m.** Dissecting the Decision: Documenting and Discussing the Clinical Practice Patterns of Hematologic Oncology Investigators in the Management of Mantle Cell Lymphoma
Educational grant support provided by AbbVie Inc., AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

ASK THE EXPERTS M

- 3:00 p.m.** Clinical Cases Discussing Treatment and Sequencing of Agents in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
MODERATOR: Thomas E. Witzig, MD
Nathan H. Fowler, MD; Leo I. Gordon, MD, FACP; and Richard I. Fisher, MD
- 4:00 p.m.** Clinical Cases Discussing Upfront, Relapsed, and Transplant Options for Patients with ALL and Lymphoblastic Lymphoma
MODERATOR: Philip J. Bierman, MD
Vijaya Raj Bhatt, MBBS; Wendy Stock, MD; and Susan M. O'Brien, MD
- 5:00 p.m.** Adjourn

CONFERENCE DINNER H

- 7:00-10:00 p.m.**
Conference Dinner Conference participants and registered accompanying guest(s) are invited to join. Name tags required.

Friday, July 20

- 7:00 a.m.** Continental Breakfast G

SCIENTIFIC SESSIONS M

Common Indolent Lymphomas

MODERATORS: Christopher J. Kratochvil, MD/Julie M. Vose, MD, MBA

- 7:30 a.m.** The Microenvironment in Indolent Lymphomas: Targeting with Combination Therapies
John G. Gribben, DSc, FRCP, FRCPath, FMedSci

- 7:55 a.m.** CLL: How To Sequence Therapy Options
Susan M. O'Brien, MD

- 8:20 a.m.** Mantle Cell Lymphoma – Controlled or Cured?
Andre H. Goy, MD, MPH

- 8:45 a.m.** Follicular Lymphoma: Novel Combination Therapies
Jonathan W. Friedberg, MD, MMSc

- 9:10 a.m.** Multiple Facets of Marginal Zone Lymphoma
Emanuele Zucca, MD

- 9:35 a.m.** Refreshment Break G

Uncommon Indolent Lymphomas

MODERATORS: Matthew A. Lunning, DO

- 9:55 a.m.** Waldenstrom's Macroglobulinemia: Optimal Treatment Sequencing
Irene M. Ghobrial, MD

- 10:20 a.m.** Best Management of LGL After Methotrexate or Cytosan
R. Gregory Bociek, MD, MSc, FRCP(C)

- 10:45 a.m.** Best Management of LyP After Methotrexate Fails
Steven M. Horwitz, MD

- 11:10 a.m.** Management of Lymphomatoid Granulomatosis
Wyndham H. Wilson, MD, PhD

- 11:35 a.m.** Clinical Trials for Patients with Lymphoma: How to Enroll More Patients
John P. Leonard, MD

- 12:00 p.m.** Take Home Messages from PPLC 2018
Matthew A. Lunning, DO

- 12:30 p.m.** Adjourn

Jeremy S. Abramson, MD

Director, Center for Lymphoma, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School, Boston, MA

Ranjana H. Advani, MD

Saul A. Rosenberg Professor of Lymphoma, Department of Medicine/Oncology, Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

Stephen M. Ansell, MD, PhD

Chair, Mayo Clinic Lymphoma Group; Professor of Medicine, Mayo Clinic, Rochester, MN

James O. Armitage, MD ★

Joe Shapiro Professor of Medicine, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Eric J. Avery, MD

Nebraska Hematology Oncology, Lincoln, NE

Nancy L. Bartlett, MD

Professor of Medicine, Koman Chair in Medical Oncology, Washington University School of Medicine, St. Louis, MO

Vijaya Raj Bhatt, MBBS

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Philip J. Bierman, MD

Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Susan Blumel, RN, BSN ★

Clinical Study Nurse Coordinator, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

R. Gregory Bociek, MD, MSc, FRCP(C)

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Peggy Burhenn, MS, RN-BC, AOCNS

Professional Practice Leader, Geriatric Oncology, City of Hope National Medical Center, Duarte, CA

Bruce D. Cheson, MD

Deputy Chief, Hematology-Oncology; Professor of Medicine; Head of Hematology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

Matthew S. Davids, MD, MMSc

Associate Director, CLL Center, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA

Daniel J. DeBehnke, MD, MBA

Chief Executive Officer, Nebraska Medicine; Professor, Department of Emergency Medicine; Senior Associate Dean – Health System, University of Nebraska Medical Center, Omaha, NE

Angela Dispenzieri, MD

Professor of Medicine; Professor of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Kieron M. Dunleavy, MD

Professor of Medicine, George Washington University; Lymphoma Program Director, George Washington Cancer Center, Washington, DC

Andreas Engert, MD

Professor of Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Cologne, Germany

Richard I. Fisher, MD

President and CEO, The Robert C. Young MD Chair in Cancer Research, Fox Chase Cancer Center – Temple Health; Senior Associate Dean, Temple University School of Medicine, Philadelphia, PA

Nathan H. Fowler, MD

Associate Professor; Director, Clinical and Translational Research, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Theresa Franco, MSN, RN

Vice President, Cancer Center Clinical Operations & Radiology, Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

Jonathan W. Friedberg, MD, MMSc

Director, James P. Wilmot Cancer Center; Samuel Durand Professor of Medicine, University of Rochester Medical Center, Rochester, NY

Irene M. Ghobrial, MD

Associate Professor of Medicine, Harvard Medical School; Director, Michele & Steven Kirsch Laboratory; Director, Clinical Investigator Research Program; Senior Physician, Dana-Farber Cancer Institute, Boston, MA

Leo I. Gordon, MD, FACP

Abby and John Friend Professor of Oncology Research; Professor of Medicine; Director, Lymphoma Program; Co-Director, Hematologic Malignancies Program, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center; Medical Director, The Mathews Center for Cellular Therapy, Northwestern Memorial Hospital, Northwestern University, Chicago, IL

Andre H. Goy, MD, MPH

Chairman and Executive Director, John Theurer Cancer Center, Hackensack University Medical Center; Chief Science Officer; Director of Research and Innovation, Regional Cancer Care Associates, Hackensack, NJ

Tara M. Graff, DO, MS

Medical Oncology and Hematology Associates of Iowa, Des Moines, IA

Timothy C. Greiner, MD

Amelia F. and Austin L. Vickery, Jr. Professor; Director of Hematopathology Fellowship, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE

John G. Gribben, MD, DSc, FRCP, FRCPath, FMed Sci

Hamilton Fairley Professor of Medical Oncology, Barts Cancer Institute, Queen Mary School of Medicine, University of London, London, England, UK

Neil J. Hansen, MD

Assistant Professor, Division of Body Imaging and Nuclear Medicine, Department of Radiology, University of Nebraska Medical Center, Omaha, NE

Sarah A. Holstein, MD, PhD

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Richard T. Hoppe, MD

Henry S. Kaplan-Henry Lebeson Professor of Cancer Biology; Professor, Radiation Oncology-Radiation Therapy; Member, Cancer Institute, Stanford University School of Medicine, Stanford, CA

CONFERENCE FACULTY

Steven M. Horwitz, MD

Associate Attending, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Brad S. Kahl, MD

Professor of Medicine; Director, Lymphoma Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

Won Seog Kim, MD, PhD

Professor, Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea

Youn H. Kim, MD

Joanne and Peter Haas, Jr. Professor; Director, Multidisciplinary Cutaneous Lymphoma Program, Stanford University School of Medicine and Cancer Institute, Stanford, CA

Christopher J. Kratochvil, MD

Associate Vice Chancellor for Clinical Research, University of Nebraska Medical Center; Vice President for Research, Nebraska Medicine; Chief Medical Officer, UNeHealth, Omaha, NE

Sandra Kurtin, PhD, ANP-C, AOCN

Nurse Practitioner, The University of Arizona Cancer Center; Clinical Assistant Professor of Medicine and Adjunct Clinical Professor of Nursing, The University of Arizona, Tucson, AZ

David M. Kurtz, MD, PhD

Postdoctoral Medical Fellow - Oncology, Stanford University, Stanford, CA

John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology; Associate Dean for Clinical Research, Weill Cornell Medical College; Vice Chairman of Medicine for Clinical Research; Associate Director, Meyer Cancer Center; Attending Physician, New York Presbyterian Hospital, New York, NY

Susanne E. Liewer, PharmD, BCOP, FHOA

Pharmacy Coordinator - Blood and Marrow Transplant, Nebraska Medicine; Clinical Associate Professor, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE

Sagar Lonial, MD

Chair and Professor, Department of Hematology and Medical Oncology; Chief Medical Officer, Winship Cancer Institute, Emory University, Atlanta, GA

Matthew A. Lunning, DO, FACP ★

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

David G. Maloney, MD, PhD

Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor of Medicine, Division of Oncology, University of Washington, Seattle, WA

Craig H. Moskowitz, MD

Physician in Chief, Cancer Service Line, Sylvester Comprehensive Cancer Center; Professor of Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL

Susan M. O'Brien, MD

Professor of Medicine; Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials and Research, University of California/Irvine, Orange, CA

Barbara Pro, MD

Professor of Medicine, Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL

Mark J. Roschewski, MD

Staff Clinician, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Katrina P. Sabati, MPA, PA-C

Physician Assistant, University of California Los Angeles (UCLA) Hematology and Bone Marrow Transplant, Los Angeles, CA

Kerry J. Savage, MD, MSc

Professor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer Agency, Vancouver, British Columbia, Canada

Stephen J. Schuster, MD

Director, Lymphoma Program; Robert and Margarita Louis-Dreyfuss Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group, BC Cancer Agency, Centre for Lymphoid Cancer; Clinical Professor, University of British Columbia, Vancouver, British Columbia, Canada

Sonali M. Smith, MD

Professor of Medicine, Section of Hematology/Oncology; Director, Lymphoma Program, The University of Chicago, Chicago, IL

Wendy Stock, MD

Anjali Seth Nayak Professor of Medicine; Director, Leukemia Program; Section of Hematology/Oncology, The University of Chicago, Chicago, IL

Julie M. Vose, MD, MBA ★

Neumann M. and Mildred E. Harris Professor and Chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Dennis D. Weisenburger, MD

Professor and Chair, Department of Pathology, City of Hope National Medical Center, Duarte, CA

Wyndham H. Wilson, MD, PhD

Deputy Chief, Lymphoid Malignancies Branch; Chief, Lymphoid Malignancy Therapeutics Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Thomas E. Witzig, MD

Professor of Medicine, Mayo Medical School; Associate Director of Translational Research; Deputy Director for Clinical Research, Mayo Clinic Cancer Center, Rochester, MN

Jasmine M. Zain, MD

Director T-Cell Lymphoma Program, Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA

Andrew D. Zelenetz, MD, PhD

Vice Chair, Medical Informatics, Department of Medicine; Attending Physician, Lymphoma Service, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College, New York, NY

Laura Zitella, MS, RN, ACNP-BC, AOCN

Lead Advanced Practice Provider/Nurse Practitioner, Inpatient Hematology/Oncology, Stanford Health Care, Stanford, CA

Emanuele Zucca, MD

Head, Lymphoma Unit, Oncology Institute of Southern Switzerland; Ospedale San Giovanni, Titular Professor of Medicine, University of Bern, Bellinzona, Switzerland

UNMC CENTER FOR CONTINUING EDUCATION

The UNMC Center for Continuing Education has been surveyed by the Accreditation Council for Continuing Medical Education (ACCME) and awarded Accreditation with Commendation for a term of six years as a provider of continuing medical education for physicians. This achievement grants UNMC CCE accreditation through July 2020 and places the Center in the highest tier of all continuing medical education providers. ACCME accreditation seeks to assure the medical community and the public that the UNMC Center for Continuing Education provides physicians with relevant, effective, practice-based continuing medical education that supports US health care quality improvement. UNMC Center for Continuing Education is one of the country's oldest accredited providers of continuing education for physicians.

The Center offers a broad range of programming (i.e., live activities, conferences, workshops, as well as self-directed learning activities and enduring materials) with content ranging from primary care issues to the latest developments in oncology and other specialties.

The Center sponsors more than 800 activities annually that reach approximately 50,000 healthcare providers from the US and worldwide.

UNMC DEPARTMENT OF INTERNAL MEDICINE - DIVISION OF ONCOLOGY AND HEMATOLOGY

Renowned for the diagnosis, therapy, and research of lymphoma, the UNMC Department of Internal Medicine, Division of Oncology and Hematology has treated patients from all over the world. Patients come for consultation, initial diagnosis, second opinions, standard chemotherapy, participation in clinical research trials, and bone marrow/stem cell transplants.

The Division of Oncology and Hematology is comprised of 24 faculty and physicians, with five specializing in lymphoma. The Division is interested in the diagnosis and treatment of all malignancies (cancers). Treatment may include chemotherapy, radiation therapy, immunotherapy, pathway targeted agents, or cellular therapies, including bone and marrow transplantation.

The Division's physicians specialize in many types of cancers including lymphomas, leukemia, multiple myeloma, urologic, breast, lung, gastric and pancreatic, neuro-oncologic, brain cancer, melanoma, hepatocellular, and other solid tumors.

UNMC COLLEGE OF NURSING CONTINUING NURSING EDUCATION

The UNMC CON CNE has been accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation since

1980. In its most recent accreditation, UNMC CON CNE was awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020. In addition, we are approved by the California Board of Registered Nursing. We are able to take accredited programs into all 50 states and beyond. UNMC CON CNE targets RNs, especially those engaged in specialty practices and those with advanced degrees, including APNs and faculty. The UNMC CON CNE provides between 150-250 accredited learning activities annually in a variety of formats, including live synchronous programs and asynchronous online activities, totaling over 83,000 CE certificates issued to date. Our highly developed technical capabilities include instructional design and module development, video streaming, hosting jointly provided learning activities, custom web development, visual design, dynamic web pages, and data collection, storage, and analysis.

NEBRASKA MEDICINE

Nebraska Medicine is the most esteemed academic health system in the region, consisting of 809 licensed beds at its two hospitals, more than 1,000 physicians and 40 specialty and primary care clinics in Omaha and surrounding areas.

Nebraska Medicine and its research and education partner, the University of Nebraska Medical Center (UNMC), share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.

Nebraska Medicine traces its roots back to 1869 with the founding of Omaha's first hospital. In the decades since, it has built an international reputation for breakthroughs in cancer care, organ transplantation and treatment of infectious diseases.

In 2017, Nebraska Medicine earned the Bernard A. Birnbaum, MD Quality Leadership Award from Vizient, Inc. which recognizes it in the top ten quality academic health systems in the United States. For five straight years, Nebraska Medicine has also been named to Becker's Hospital Review's list of 100 Great Hospitals in America.

FRED & PAMELA BUFFETT CANCER CENTER

The UNMC Fred and Pamela Buffett Cancer Center is the region's only National Cancer Institute (NCI) designated cancer center and is a member of the National Comprehensive Cancer Network (NCCN). The NCCN is an alliance of the nation's 27 leading cancer centers that develop and institute standards of care for the treatment of cancer and perform outcomes research with the goal of ensuring the delivery of high quality, cost-effective services to cancer patients nationwide.

CONFERENCE SPONSORS

The Fred & Pamela Buffett Cancer Center has begun changing forever the way cancer is diagnosed and treated. By harnessing the most advanced biomedical and technological tools available, we are increasingly identifying the drivers behind cancer and creating precise therapies that improve outcomes. Through the use of genomics and other new diagnostic tools, we are employing precision medicine to customize therapies and care for each cancer patient.

While all forms of cancer will be treated at the Fred & Pamela Buffett Cancer Center, because of their prevalence in society and the center's potential to have a significant impact in their treatment, the following focus areas have been selected: Breast Cancer and Other Women's Cancers, Head and Neck Cancers, Leukemia and Lymphoma, Lung Cancer, Pancreatic and Gastrointestinal Cancers, and Prostate Cancer.

POSTGRADUATE INSTITUTE FOR MEDICINE

The Postgraduate Institute for Medicine has been providing trusted independent continuing education for healthcare professionals for over thirty (30) years and is a recognized leader for jointly provided continuing education activities. The purpose of the PIM continuing medical education (CME) program is to deliver effective CME activities that are designed to contribute to the professional development of physicians, as well as other healthcare professionals, support their lifelong learning process and positively impact the delivery of medical care. We fulfill

this mission by forming successful alliances and working in collaboration to deliver impactful educational experiences that are designed to improve patient care practices.

PIM is Accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Psychological Association (APA) and is Accredited with Distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission (ANCC) on Accreditation. PIM is among a very select number of accredited organizations that have demonstrated the highest levels of quality and excellence in the delivery of both continuing physician and nursing education and also meets the qualifications for continuing education credit for MFTs, LPCCs, LEPs and / or LCSWs as required by the California Board of Behavioral Sciences and is an American Dental Association (ADA) CERP Recognized Provider.

The mission of PIM is to improve patient care by identifying gaps in physician knowledge, competence and/or performance and to provide effective educational interventions for the purpose of enhancing the knowledge and attitudes of our learners to positively impact patient care and well-being.



Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.



Complimentary WiFi available

Network: UNMCPPLC18

Password: PPLC2018

Supported by AbbVie Inc., AstraZeneca and Acerta Pharma, a member of the AstraZeneca Group, and Gilead Sciences, Inc.



**Congratulations to our
2018 PPLC Abstract
Travel Stipend Recipients**

Ryohei Abe, MD
Maria Badillo, MSN, RN
Nassoma Bumpers, PA-C
Wendy Chen, PA-C
Talal Hilal, MD
Michelle Lee, MD
Saidrakhim Lukmonov, MD
Cecilia Rosand, PA-C
Cinnie Soekojo, MD
Kelly Syzmanski, NP
Yucai Wang, MD, PhD

2020 PAN PACIFIC
LYMPHOMA
CONFERENCE

SAVE THE DATE **July 20-25**

The Fairmont Orchid / **BIG ISLAND, HAWAII**



www.unmc.edu/panpacificlymphoma